EmbarkNeuro - About the company
EmbarkNeuro is an unfunded company based in Oakland (United States), founded in 2021 by Mark Fishman and Joe Jimenez. It operates as a Developer of therapeutics for the treatment of mental health disorders. EmbarkNeuro has not raised any funding yet. The company has 4 active competitors, including 1 funded and 2 that have exited. Its top competitors are Tonix Pharma, Draigtherapeutics and Naurex.
Company Details
Developer of therapeutics for the treatment of mental health disorders. The company is focusing on identifying depressed individuals with a potential biomarker linked to the stress response system and developing ANC-501 for patients with Depression.
- Website
- embarkneuro.com
- Email ID
- *****@embarkneuro.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2021
Location
Oakland, United States
Stage
Unfunded
Ranked
4th among 4 active competitors
Similar Companies
Sign up to download EmbarkNeuro's company profile
EmbarkNeuro's funding and investors
EmbarkNeuro has not raised any funding rounds yet.
EmbarkNeuro's founders and board of directors
Founder? Claim ProfileThe founders of EmbarkNeuro are Mark Fishman and Joe Jimenez. Stephen Kanes is the CEO of EmbarkNeuro.
Here are the details of EmbarkNeuro's key team members:
- Mark Fishman: Co-Founder of EmbarkNeuro.
- Joe Jimenez: Co-Founder & Managing Director of EmbarkNeuro.
- Stephen Kanes: CEO of EmbarkNeuro.
View details of EmbarkNeuro's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
EmbarkNeuro's Competitors and alternates
Top competitors of EmbarkNeuro include Tonix Pharma, Draigtherapeutics and Naurex. Here is the list of Top 10 competitors of EmbarkNeuro, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Tonix Pharma 2007, New York City (United States), Public | Developer of next-generation medicines for CNS and immunological disorders | $4.45M | 67/100 | |
2nd | ![]() Draigtherapeutics 2021, Cardiff (United Kingdom), Series B | Developer of targeted neuromodulators for neuropsychiatric disorders treatment | $205M | 60/100 | |
3rd | Naurex 2008, Evanston (United States), Acquired | Clinical-stage company developing novel therapies for depression and other CNS disorders. | $162M | 46/100 | |
4th | EmbarkNeuro 2021, Oakland (United States), Unfunded | Developer of therapeutics for the treatment of mental health disorders | - | - | 28/100 |
Looking for more details on EmbarkNeuro's competitors? Click here to see the top ones
EmbarkNeuro's Investments and acquisitions
EmbarkNeuro has made no investments or acquisitions yet.
Reports related to EmbarkNeuro
Here is the latest report on EmbarkNeuro's sector:
News related to EmbarkNeuro
•
Embarkneuro Announces Initiation Of Phase 2 Trial Of Anc-501, A First-in-class, V1b Receptor Antagonist For The Personalized Treatment Of DepressionPipelinereview•Nov 21, 2022•EmbarkNeuro
Are you a Founder ?
FAQs about EmbarkNeuro
Explore our recently published companies
- Hallam Truck Centre - Hallam based, 1934 founded, Unfunded company
- Luxe Auto Lounge - Ottawa based, 2004 founded, Unfunded company
- Mark Serrate - Spain based, Unfunded company
- Grace Hartounian - Los Angeles based, Unfunded company
- GPT Cash - Unfunded company
- Good Girls Gone Boss - Unfunded company

